116 related articles for article (PubMed ID: 19665225)
1. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study.
Chun K; Hagemeijer A; Iqbal A; Slovak ML
Leuk Res; 2010 Feb; 34(2):160-5. PubMed ID: 19665225
[TBL] [Abstract][Full Text] [Related]
2. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
4. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
6. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
[TBL] [Abstract][Full Text] [Related]
7. [Cytogenetic profile in patients with primary myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Petrova EV; Martynenko LS; Ivanova MP; Aksenova VIu; Tsybakova NIu; Potikhonova NA; Abdulkadyrov KM
Ter Arkh; 2013; 85(7):43-9. PubMed ID: 24137946
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
Breccia M; Mancini M; Nanni M; D'Elia GM; Carmosino I; Latagliata R; Sarlo C; Mandelli F; Alimena G
Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype.
Schwabkey ZI; Al Ali N; Chan O; Sallman DA; Padron E; Kuykendall AT; Talati C; Sweet K; Lancet JE; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e52-e56. PubMed ID: 33093008
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW
Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
12. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
Fenaux P
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
[TBL] [Abstract][Full Text] [Related]
13. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
Arenillas L; Mallo M; Ramos F; Guinta K; Barragán E; Lumbreras E; Larráyoz MJ; De Paz R; Tormo M; Abáigar M; Pedro C; Cervera J; Such E; José Calasanz M; Díez-Campelo M; Sanz GF; Hernández JM; Luño E; Saumell S; Maciejewski J; Florensa L; Solé F
Genes Chromosomes Cancer; 2013 Dec; 52(12):1167-77. PubMed ID: 24123380
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
17. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.
Valent P; Horny HP
Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
20. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]